Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
Psychedelics have shown promise in treating various mental health issues, including PTSD and depression, but they’ve often faced notable challenges. Side effects like nausea, cardiovascular risks, and the potential for “bad trips” have raised concerns among both clinicians and patients. As Time reported, companies like Mindstate Design Labs and Atai Life Sciences (NASDAQ:ATAI) are developing new forms of psychedelics, sometimes called Psychedelics 2.0, designed to offer therapeutic benefits with fewer risks.
Challenges And Limitations Of Traditional Psychedelics
Traditional psychedelics like psilocybin, MDMA and LSD work by promoting neuroplasticity, which helps the brain form new connections and process trauma. However, these substances can be time-intensive, sometimes requiring patients to endure hours-long sessions under medical supervision. This protocol not only strains mental health resources but can also be daunting for patients.
Dillan DiNardo, CEO of Mindstate Design Labs, describes classic psychedelics …